Logo image of TCMD

TACTILE SYSTEMS TECHNOLOGY I (TCMD) Stock Price, Forecast & Analysis

USA - NASDAQ:TCMD - US87357P1003 - Common Stock

24.37 USD
-0.22 (-0.89%)
Last: 11/13/2025, 8:00:01 PM
24.37 USD
0 (0%)
After Hours: 11/13/2025, 8:00:01 PM

TCMD Key Statistics, Chart & Performance

Key Statistics
Market Cap543.21M
Revenue(TTM)311.51M
Net Income(TTM)18.17M
Shares22.29M
Float21.69M
52 Week High25.42
52 Week Low8.61
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.77
PE31.65
Fwd PE27.27
Earnings (Next)02-16 2026-02-16/amc
IPO2016-07-28
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


TCMD short term performance overview.The bars show the price performance of TCMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

TCMD long term performance overview.The bars show the price performance of TCMD in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of TCMD is 24.37 USD. In the past month the price increased by 65.9%. In the past year, price increased by 55.62%.

TACTILE SYSTEMS TECHNOLOGY I / TCMD Daily stock chart

TCMD Latest News, Press Relases and Analysis

TCMD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.9 224.97B
ISRG INTUITIVE SURGICAL INC 65.68 202.72B
BSX BOSTON SCIENTIFIC CORP 35.59 155.55B
SYK STRYKER CORP 28.35 142.76B
IDXX IDEXX LABORATORIES INC 55.63 56.12B
BDX BECTON DICKINSON AND CO 13.39 55.33B
EW EDWARDS LIFESCIENCES CORP 33.51 50.56B
RMD RESMED INC 25.47 36.79B
GEHC GE HEALTHCARE TECHNOLOGY 16.12 33.77B
PODD INSULET CORP 72.79 23.42B
DXCM DEXCOM INC 32.11 23.42B
ZBH ZIMMER BIOMET HOLDINGS INC 11.2 17.94B

About TCMD

Company Profile

TCMD logo image Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,037 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.

Company Info

TACTILE SYSTEMS TECHNOLOGY I

3701 Wayzata Blvd, Suite 300

Minneapolis MINNESOTA 55416 US

CEO: Daniel L. Reuvers

Employees: 1037

TCMD Company Website

TCMD Investor Relations

Phone: 18333822845

TACTILE SYSTEMS TECHNOLOGY I / TCMD FAQ

Can you describe the business of TACTILE SYSTEMS TECHNOLOGY I?

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,037 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.


What is the current price of TCMD stock?

The current stock price of TCMD is 24.37 USD. The price decreased by -0.89% in the last trading session.


Does TCMD stock pay dividends?

TCMD does not pay a dividend.


What is the ChartMill rating of TACTILE SYSTEMS TECHNOLOGY I stock?

TCMD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is TACTILE SYSTEMS TECHNOLOGY I (TCMD) stock traded?

TCMD stock is listed on the Nasdaq exchange.


How is the market expecting TCMD stock to perform?

11 analysts have analysed TCMD and the average price target is 17.17 USD. This implies a price decrease of -29.54% is expected in the next year compared to the current price of 24.37.


What is the employee count for TCMD stock?

TACTILE SYSTEMS TECHNOLOGY I (TCMD) currently has 1037 employees.


TCMD Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TCMD. When comparing the yearly performance of all stocks, TCMD is one of the better performing stocks in the market, outperforming 95.6% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TCMD Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to TCMD. TCMD has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TCMD Financial Highlights

Over the last trailing twelve months TCMD reported a non-GAAP Earnings per Share(EPS) of 0.77. The EPS increased by 16.67% compared to the year before.


Industry RankSector Rank
PM (TTM) 5.83%
ROA 7.01%
ROE 8.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%71.43%
Sales Q2Q%17.32%
EPS 1Y (TTM)16.67%
Revenue 1Y (TTM)9.28%

TCMD Forecast & Estimates

11 analysts have analysed TCMD and the average price target is 17.17 USD. This implies a price decrease of -29.54% is expected in the next year compared to the current price of 24.37.

For the next year, analysts expect an EPS growth of -11.22% and a revenue growth 6.59% for TCMD


Analysts
Analysts78.18
Price Target17.17 (-29.54%)
EPS Next Y-11.22%
Revenue Next Year6.59%

TCMD Ownership

Ownership
Inst Owners100.61%
Ins Owners2.67%
Short Float %8.96%
Short Ratio10.92